Ilgen Mender

Title: Ilgen Mender: Innovator in Cancer Treatment

Introduction

Ilgen Mender is a notable inventor based in Dallas, TX (US), recognized for his contributions to cancer treatment through innovative pharmaceutical methods. He holds 2 patents that focus on advanced therapies for combating cancer and other hyperproliferative diseases.

Latest Patents

Mender's latest patents include groundbreaking methods for the sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors, and radiation therapy. This invention discloses methods that utilize a telomerase-mediated telomere-targeting drug, 6-thio-2'-deoxyguanosine (6-thio-dG), in combination with checkpoint inhibitors and/or radiation therapy. The approach has shown promise in leading to tumor regression through innate and adaptive immune-dependent mechanisms in syngeneic and humanized mouse cancer models.

Another significant patent focuses on the treatment of drug-resistant proliferative diseases with telomerase-mediated telomere-altering compounds. This invention describes pharmaceutical compositions and methods that employ 6-mercaptopurine ribosides and their analogues for treating cancer and other hyperproliferative diseases. The compounds can be converted into telomere substrates in vivo, allowing for recognition by telomerase, which leads to the induction of cell death in telomerase-active cells.

Career Highlights

Ilgen Mender is affiliated with the University of Texas System, where he continues to advance research in cancer therapies. His work has significantly impacted the field of oncology, providing new avenues for treatment.

Collaborations

Mender collaborates with esteemed colleagues, including Jerry W. Shay and Kimberly Batten, who contribute to his research endeavors.

Conclusion

Ilgen Mender's innovative work in cancer treatment exemplifies the potential of targeted therapies in improving patient outcomes. His patents reflect a commitment to advancing medical science and addressing the challenges posed by cancer.